Abstract | OBJECTIVES: METHODS: RESULTS: Combination therapy with sitagliptin and Pro3(GIP) resulted in significantly greater reductions of blood glucose and triglycerides than either monotherapy. Combination therapy also improved insulin sensitivity and glucose tolerance. β-cell mass and insulin-positive cell percentage in the pancreas was higher in mice receiving combination therapy compared with either monotherapy. Crown-like structures, inflammatory markers in adipose tissue, and serum leptin concentrations were decreased in mice receiving combination therapy compared with either monotherapy. CONCLUSIONS: Combination therapy with Pro3(GIP) and sitagliptin improved metabolic abnormalities in diabetic mice. Changes in serum leptins and reduced inflammatory cell infiltration in adipose tissue might account for the observed effects.
|
Authors | Fei Yang, Shan Dang, Hongjun Lv, Bingyin Shi |
Journal | The Journal of international medical research
(J Int Med Res)
Vol. 49
Issue 1
Pg. 300060520985664
(Jan 2021)
ISSN: 1473-2300 [Electronic] England |
PMID | 33512261
(Publication Type: Journal Article)
|
Chemical References |
- Blood Glucose
- Insulin
- Protease Inhibitors
- Receptors, Gastrointestinal Hormone
- Gastric Inhibitory Polypeptide
- gastric inhibitory polypeptide receptor
|
Topics |
- Animals
- Blood Glucose
- Diabetes Mellitus, Experimental
(drug therapy)
- Diabetes Mellitus, Type 2
(drug therapy)
- Gastric Inhibitory Polypeptide
- Insulin
- Mice
- Mice, Inbred C57BL
- Protease Inhibitors
- Receptors, Gastrointestinal Hormone
|